Long COVID remains a major public health challenge, with BioVie pursuing a CNS-focused therapy to address brain fog, fatigue, and malaise linked to lingering immune activation after initial infection.

BioVie CEO Cuong Do notes there are approximately 17 million affected Americans and no approved therapies specifically for long COVID.

The company’s clinical program targets central nervous system symptoms, aiming to mitigate neurological and systemic effects believed to stem from immune activation driven by viral remnants.

Do emphasizes the program’s potential impact, given the lack of approved treatments and the possibility for meaningful clinical and public health benefits if results are positive.

Enrollment for the long COVID trial is nearing completion, with top-line data anticipated by the end of the summer to assess efficacy and safety.

This near-term milestone of finalizing enrollment and obtaining top-line results is critical for evaluating the treatment’s potential.

Do remains optimistic about the trial’s progress and its potential to restore daily functioning and work ability for patients with lingering symptoms.

The program is supported by a $13 million clinical research grant, underscoring urgency and positioning BioVie as uniquely funded for this long COVID work.

BioVie claims it is the only entity at any level to receive such a grant for long COVID research from a nonprofit or related organization.

With no approved long COVID therapies, BioVie’s program could become first-in-class if successful and address unmet medical needs.

BioVie asserts its unique positioning in this space and highlights the importance of completing enrollment and achieving meaningful results to validate their CNS-focused approach.

The approach aims to improve daily functioning and help patients resume normal activities by treating CNS-related post-acute effects.